(Q38036715)

English

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

metastatic melanoma

1 reference

based on heuristic

inferred from title

Julia A Newton Bishop

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

R Sinha

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

K Edmonds

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M E Gore

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

J Larkin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

L Fearfield

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

0 references

publication date

1 November 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

British Journal of Dermatology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

167

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

987-994

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Revised U.K. guidelines for the management of cutaneous melanoma 2010

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Somatic activation of KIT in distinct subtypes of melanoma

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

KIT as a therapeutic target in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

BRAF kinase gene V599E mutation in growing melanocytic lesions

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Sorafenib-induced premalignant and malignant skin lesions

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

The histologic spectrum of epithelial neoplasms induced by sorafenib

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12010

21 January 2018

Identifiers

10.1111/BJD.12010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22913467%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38036715&oldid=1511401964"